HLA-C and neoplasm: As shown in Figure 2, after generating tumor-derived antigens, antigen-presenting cells (APCs) such as dendritic cells (DCs) capture the antigens and then transport them to draining lymph nodes for activating T cells, which then traffic to tumor sites and specifically recognize cancer cells via the interactions of T cell receptors (TCRs) and major histocompatibility complex class (MHC) molecules, leading to the killing of cancer cells with antigenic release and thus triggering the autoloop of the cancer immunity cycle with a continuous anti-tumor immune effect.